Impact Biomedical Inc. will conduct a 1-for-12.62 reverse stock split on September 23, 2026, consolidating shares without changing shareholder value. This move facilitates its planned merger with Zoar Ltd., with a Form F-4 registration filed with the SEC. Post-split, each Impact share will convert to one Zoar share, correcting a prior 1-for-4 exchange announcement. The merger awaits SEC approval and regulatory clearance to proceed.
Impact Biomedical's reverse stock split and merger plans provide context for readers. For those tracking health-sector stocks, 66 of 91 priced US stocks rose today on Pluang. Notable movers include Inovio Pharmaceuticals Inc (INO) at USD 1.22 with a 5.65% increase, Enveric Biosciences Inc (ENVB) at USD 1.57 up 5.37%, and Cassava Sciences Inc (FLNA) at USD 0.72 rising 5.23%, as of Sep 18, 2026 01:31 WIB.
An investment of $10,000 in Nebius when it resumed trading in 2024 has grown significantly to approximately $105,000 by 2026. This remarkable increase highlights Nebius's strong market performance over the two-year period. Investors who bought in at ...
W.P. Carey expects to invest over $1.9 billion in 2026, reflecting robust growth in its net lease property portfolio. Despite a slight reduction in its price target by Scotiabank to $76, the stock still shows potential upside from current levels. The...
Qualcomm's stock rose 18% over the past month, outperforming the broader chip market but lagging behind smartphone chip peers Skyworks Solutions (33%) and Qorvo (23%). The rally was driven by a narrow rotation into smartphone chip suppliers, not a br...
Rosen Law Firm has filed a class action lawsuit against AppLovin Corporation for allegedly making false and misleading statements about delays and overstated benefits of its generative AI video creative feature between February and August 2026. The l...
Paramount Skydance is lobbying California Democrats, including LA Mayor Karen Bass, to isolate Attorney General Rob Bonta over his antitrust lawsuit challenging their $81 billion merger with Warner Bros. Discovery. The company argues the case is weak...
